Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.96

Genmab A/S (NASDAQ:GMABGet Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $29.96, but opened at $29.35. Genmab A/S shares last traded at $29.50, with a volume of 311,725 shares trading hands.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Citigroup downgraded Genmab A/S from a “neutral” rating to a “sell” rating in a research report on Monday, January 22nd. Morgan Stanley reiterated an “underweight” rating on shares of Genmab A/S in a research report on Tuesday, March 26th. UBS Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, December 6th. Truist Financial reiterated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Tuesday, March 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Wednesday, March 27th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $48.50.

Get Our Latest Report on Genmab A/S

Genmab A/S Price Performance

The stock has a market capitalization of $19.29 billion, a price-to-earnings ratio of 31.21, a PEG ratio of 1.41 and a beta of 0.99. The business has a 50 day simple moving average of $29.00 and a 200-day simple moving average of $30.84.

Genmab A/S (NASDAQ:GMABGet Free Report) last issued its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. The company had revenue of $675.29 million for the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. As a group, equities analysts predict that Genmab A/S will post 1.09 earnings per share for the current year.

Institutional Trading of Genmab A/S

A number of institutional investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. lifted its holdings in shares of Genmab A/S by 1.7% in the first quarter. Rockefeller Capital Management L.P. now owns 18,508 shares of the company’s stock valued at $698,000 after purchasing an additional 310 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Genmab A/S by 5.7% during the third quarter. Ameriprise Financial Inc. now owns 6,268 shares of the company’s stock worth $221,000 after acquiring an additional 337 shares in the last quarter. Geode Capital Management LLC raised its holdings in Genmab A/S by 1.0% during the second quarter. Geode Capital Management LLC now owns 41,715 shares of the company’s stock worth $1,586,000 after acquiring an additional 408 shares in the last quarter. HBK Sorce Advisory LLC raised its holdings in Genmab A/S by 4.8% during the third quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company’s stock worth $322,000 after acquiring an additional 419 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Genmab A/S by 86.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock worth $38,000 after acquiring an additional 498 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Further Reading

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.